INTRODUCTION:

According to the World Health Organization (WHO), infertility is the inability to achieve pregnancy after 12 months or more of regular unprotected intercourse.¹ It's a prevalent issue, impacting around 10 to 15% of couples globally. In the United States, ovulatory disorders contribute to 30-40% of female infertility, while male infertility accounts for 25%.² Globally, an estimated 60-80 million couples, approximately 25% of them in India, experience infertility.

This condition not only poses medical challenges but also has profound psychological implications.³ Addressing infertility requires comprehensive medical care and support, acknowledging its significant impact on individuals and couples alike. Effective interventions and support systems are crucial in managing this complex issue and providing hope for those affected by it.⁴

According to a 2012 study by the WHO, one in four couples in developing countries is affected by infertility, impacting their quality of life significantly.⁵The WHO defines quality of life as an individual's perception of their position in life within cultural and value systems, encompassing goals, expectations, and concerns.⁶ It is influenced by physical health, psychological state, independence level, social factors, personal beliefs, and environment.⁷Health-related quality of life encompasses physical, mental, emotional, and social well-being related to a disease or its treatment.⁸Infertility, often accompanied by complex treatments and stress, can lead to chronic physical illness, stress, and dissatisfaction with life compared to fertile individuals.⁹ It adversely affects mental, communication, and sexual health in affected couples. Infertility thus poses multifaceted challenges, impacting various aspects of individuals' well-being and relationships.¹⁰

A variety of diagnostic tests are available to investigate infertility in couples, with the most widely agreed-upon protocol including semen analysis, mid-luteal progesterone estimation, hysterosalpingogram, and laparoscopy in most cases.¹¹ Additional tests may be necessary for specific conditions like azoospermia, amenorrhea, or hyperprolactinemia, guided by medical history and physical examination findings. These additional tests may include the post-coital test, endometrial biopsy, and sperm antibody assay^.2

The selection of diagnostic tests is influenced by various factors such as the duration of infertility, accessibility to healthcare, and the preferences of the couple.¹²In some cases, the distance to healthcare facilities may impact the choice of diagnostic assessments. Medications are often utilized to assist with ovulation, which is the process of the ovary releasing an egg. Ovulation typically occurs once a month until menopause but may be irregular or absent due to various reasons. Hormones called gonadotrophins play a crucial role in regulating ovulation. By addressing ovulation issues through medication, healthcare providers aim to improve the chances of conception for couples struggling with infertility^.13

Gonadotropins, hormones produced by the pituitary gland situated just under the brain, play a crucial role in regulating reproductive functions.¹⁴ These hormones, namely Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), stimulate the activity of the gonads—ovaries in women and testes in men. Upon release into the bloodstream, FSH and LH travel to the ovaries, where they trigger processes essential for ovulation to occur. By stimulating the ovaries, these gonadotropins facilitate the maturation and release of eggs, promoting fertility in women. Similarly, in men, FSH and LH regulate spermatogenesis, the production of sperm cells, and other aspects of reproductive function. The intricate interplay between these hormones and the reproductive organs is essential for the maintenance of fertility and overall reproductive health.¹⁵

MATERIALS AND METHODS:

Study Site:

The cohort study was carried out at Shree Krishna Hospital and Medical Research Centre in Karamsad, Anand, India, following approval from the Institutional Ethics Committee (IEC), with the reference number IEC/HMPCMC/86/Faculty/2/296/17.

Sample Size:

The study sample size consist of 50 female patients who were undergoing assisted infertility treatment at Gynaecological Department of Shree Krishna Hospital in Karamsad, specifically those attending outpatient appointments (OPD-based patients).

Inclusion and Exclusion Criteria:

Inclusion Criteria:

· The study focused on patients seeking treatment for infertility at the Gynaecological Department of Shree Krishna Hospital in Karamsad, specifically those attending outpatient appointments (OPD-based patients).

· Patients experiencing primary infertility (difficulty conceiving with no previous pregnancies) and secondary infertility (difficulty conceiving after a previous successful pregnancy) were included in the study.

· Patients with the ability to comprehend and respond to study assessments and questionnaires.

· Patients willing to participate in the study and provide informed consent.

Exclusion Criteria:

· Patients with severe medical conditions that contraindicate fertility treatments.

· Patients with significant psychological or psychiatric conditions that may affect their ability to participate in the study or adhere to treatment regimens.

· Patients unwilling or unable to provide informed consent for participation in the study.

Data collection:

The study commenced following approval from the Institutional Ethics Committee of the hospital. It involved fifty infertile patients who presented at the Gynaecological Department between December 2017 and June 2018. The Quality of Life (QoL) of these patients was assessed using Ferti-QoL questionnaires, which evaluated various parameters including Emotional, Mind/Body, Relational, Social, Environment, and Tolerability aspects of infertility.

The Mind/Body subscale score gauged the impact of infertility on physical health, cognitive health, and behavior, while the Relational subscale score assessed its effects on relationship components such as sexuality, communication, and commitment. The Social subscale score indicated the impact of fertility problems on social interactions and support systems. The Tolerability subscale score measured the mental and physical symptoms resulting from fertility treatment and their impact on daily life. Lastly, the Environment subscale score evaluated how the accessibility and quality of treatment influenced the overall quality of life.

By utilizing these comprehensive measures, the study aimed to gain insight into the multifaceted effects of infertility on patients' lives, encompassing emotional, psychological, relational, and social dimensions, as well as the impact of fertility treatments on their well-being and daily functioning.

Statistical Analysis:

The study assessed variables using both the Paired t-test and exploratory data analysis techniques. Descriptive statistics, including mean and standard deviation (SD), were employed for exploratory data analysis to provide insights into the data distribution and central tendency.

To compare the quality of life (QoL) before and after treatment, paired t-tests were conducted on total QoL scores. This statistical method allowed for the examination of changes in QoL within the same group of patients over time, accounting for individual differences.

By utilizing these analytical approaches, the study aimed to evaluate the effectiveness of treatment interventions in improving the overall QoL of infertile patients, providing valuable insights into the impact of interventions on various aspects of patients' well-being.

RESULTS:

Causes Associated with Infertility:

The study comprised 50 female patients seeking infertility treatment at Shree Krishna Hospital in Karamsad. These patients were initially evaluated by physicians to confirm their infertility status. Once diagnosed as infertile, clinical tests such as Hysterosalpingography (HSG) and sonography were prescribed to identify potential causes of infertility.

Among the 50 patients, the distribution of infertility causes was as follows: 16 (32%) were diagnosed with infertility due to Tubal factors, 14 (28%) had ovulatory disorders, 7 (14%) were affected by endometriosis, and 13 (26%) experienced infertility attributed to unexplained factors, as illustrated in Table No. 1. This breakdown highlights the diverse etiology of infertility among the study participants, emphasizing the importance of thorough diagnostic evaluation to tailor treatment approaches effectively.

Table No 1: Causes associated with infertility.

Sr. No	Causes	No. of Patients	Percentage (%)
1.	Tubal Factors	16	32
2.	Ovulatory Disorder	14	28
3.	Endometriosis	07	14
4.	Unexplained	13	26

Several risk factors are commonly associated with infertility in women. These include advanced age, smoking habits, regular alcohol consumption, being either over or underweight, and excessive caffeine intake. Menstrual cycle irregularities and reproductive organ infections, including sexually transmitted infections (STIs), are also significant contributors to infertility. However, perhaps the most prevalent risk factor identified is stress.

While no single risk factor is solely responsible for infertility, the presence of multiple risk factors tends to increase the likelihood of developing infertility. Therefore, addressing these risk factors through lifestyle modifications, preventive measures, and appropriate medical interventions can play a crucial role in mitigating the risk of infertility and improving reproductive health outcomes.

Effect of Fertility Inducing Drugs:

During the study, different fertility-inducing drugs were prescribed to patients based on their specific causes of infertility and associated risk factors. Of the total participants, 22 patients received Letrozole, 18 were treated with Clomiphene citrate, and 10 were prescribed metformin.

Table No. 2: Effect of Fertility Inducing Drugs

Sr. No	Name of Drug	Drug prescribed to no. of Patients	No. of Patients received fertility	Result in Percentage (%)
1.	Letrozole	22	12	54.54
2.	Clomiphene	18	10	55.55
3.	Metformin	10	03	30.00

The observed rates of fertility among the patients receiving treatment were as follows: 54.54% of females treated with Letrozole achieved fertilization, 55.55% of females treated with Clomiphene citrate achieved fertilization, and 30% of females treated with metformin achieved fertilization, as depicted in Table No. 2.

These findings highlight the varying effectiveness of different fertility-inducing medications in facilitating fertilization among infertile patients, underscoring the importance of personalized treatment approaches tailored to individual patient profiles and underlying causes of infertility.

FertiQoL Questionnaires Compliance:

The study findings indicate a significant improvement in the quality of life (QoL) of infertile patients following treatment, with all data showing statistical significance as shown in Table No.3.

Table No. 3: FertiQoL Questionnaires Compliance

Parameter	Before Treatment (Mean)	After Treatment (Mean)	Standard Deviation		Std. Error of Mean		P Value
Parameter	Before Treatment (Mean)	After Treatment (Mean)	Before Treatment	After Treatment	Before Treatment	After Treatment	P Value
Emotional	23.33	27.50	7.51	5.76	1.50	1.15	0.0308^*
Mind/Body	23.50	28.00	7.59	6.53	1.51	1.30	0.0471^*
Relational	24.50	28.16	8.68	6.39	0.97	1.27	0.0311^*
Social	23.83	28.00	6.68	5.95	1.391	1.19	0.0464^*
Environmental	-	22.00	-	5.17	-	-	-
Tolerability	-	24.75	-	5.25	-	-	-

Top of Form

Before treatment, the emotional level of infertile females was measured at 23.33±7.511, which increased to 27.5± 5.76 after treatment. This suggests a notable enhancement in patients' emotional well-being concerning their feelings toward family and society.

Similarly, the mind/body level, reflecting physical health and behavior, increased from 23.5±7.59 before treatment to 28±6.5 after treatment. This indicates improvement in patients' overall physical and behavioral aspects following treatment.

The relational level, which assesses aspects like sexuality, communication, and commitment in relationships, also saw improvement, rising from 24.5± 8.68 before treatment to 28.16±6.39 after treatment.

The social subscale score, indicating the impact of fertility problems on social interactions, showed a significant increase from 23.83±6.68 before treatment to 28±5.95 after treatment.

However, the data reveal a lower tolerability rate among patients (24.75±5.25) and a relatively lower environmental rate (22.00±5.17) before treatment, suggesting that patients may have experienced challenges and discomfort during treatment, including interactions with hospital staff.

Overall, the study highlights the positive impact of treatment on various aspects of infertile patients' quality of life, including emotional well-being, physical health, relational dynamics, and social interactions. However, it also underscores the importance of addressing factors affecting patients' comfort and tolerance during treatment to further enhance their overall experience and outcomes.

DISCUSSION:

The findings of our investigation highlight the diverse array of factors contributing to female infertility, including endometriosis, tubal defects, chromosome abnormalities, ovulatory disorders, lifestyle factors, occupational hazards, and psychological influences. Particularly notable is the association between environmental hazards, such as pesticides and solvents, and significant alterations in fertility characteristics among the consulting population.

This study also revealed that both clomiphene and Letrozole demonstrated efficacy as fertility-inducing drugs. Treatment with clomiphene and Letrozole significantly increased the likelihood of ovulation, conception, pregnancy, and live birth, while also reducing the chances of miscarriage.

However, further research by Richard S. L. suggested that Letrozole may be more effective as a fertility inducer drug in cases of polycystic ovary syndrome (PCOS), resulting in a higher cumulative number of live births compared to clomiphene.¹⁶ It's worth noting that both Letrozole and clomiphene are classified as category X drugs under FDA guidelines, although clomiphene is approved for ovulation induction.

This study also revealed significant improvements in the quality of life of infertile-patients post-treatment. FertiQoL questionnaires highlighted improvements in relational aspects such as sexuality, communication, and commitment in relationships or partnerships after treatment with fertility-inducing drugs. Additionally, social issues, including deficiencies in social interaction, were addressed, with notable improvements observed in expectations and support post-treatment.

Furthermore, this study indicated enhancements in physical health, cognitive health, and behavior among infertile women following treatment, underscoring the broader positive impacts of fertility interventions on overall well-being.

In conclusion, our findings emphasize the multifaceted nature of infertility and underscore the effectiveness of clomiphene citrate and Letrozole for ovulation induction in infertile women. Moreover, our study highlights the gradual improvement in the quality of life of infertile patients following treatment with fertility-inducing drugs, offering hope and encouragement to those grappling with infertility.

CONCLUSION:

In summary, the present study provides comprehensive insights into the factors contributing to female infertility, including endometriosis, tubal defects, chromosome abnormalities, ovulatory disorders, lifestyle factors, occupational influences, and psychological factors. Additionally, several risk factors, such as older age, smoking, heavy alcohol use, reproductive organ infections, exposure to environmental hazards, high caffeine intake, menstrual cycle problems, and stress, were identified as significant contributors to female infertility.

Furthermore, the study revealed that both clomiphene and Letrozole exhibited comparable effectiveness as fertility-inducing drugs when compared to metformin. This finding underscores the potential of these medications in addressing infertility issues in women.

Importantly, the study also suggested that the use of fertility-inducing drugs led to an improvement in the quality of life for infertile patients. This positive impact on overall well-being highlights the potential benefits of fertility treatments beyond their primary reproductive outcomes. In conclusion, the study contributes valuable information to our understanding of female infertility, its causes, and associated risk factors, while also highlighting the positive impact of certain fertility-inducing drugs on the quality of life of individuals experiencing infertility.

ACKNOWLEDGEMENT:

The authors extend their gratitude to Shree Krishna Hospital, Karamsad, and sincerely appreciate the invaluable contribution of the patients, whose participation was integral to the successful completion of this research study.

REFERENCES:

1. World health organization. (2017). Accessed: September 5: https://www.who.int/news-room/fact-sheets/detail/infertility#:~:text=Infertility%20is%20a%20disease%20of,on%20their%20families%20and%20communities.

2. Agarwal, A., Mulgund, A., Hamada, A. et al. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015; 13: 37. https://doi.org/10.1186/s12958-015-0032-1

3. Adamson, P. C., Krupp, K., Freeman, A. H., Klausner, J. D., Reingold, A. L., and Madhivanan, P. Prevalence and correlates of primary infertility among young women in Mysore, India. The Indian Journal of Medical Research. 2011; 134(4): 440–446.

4. Infertility (2017) World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/infertility (Accessed: 05 October 2017).

5. 1 in 6 people globally affected by infertility: Who (no date) World Health Organization. Available at: https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility (Accessed: 05 October 2017).

6. WHOQOL - measuring quality of life| The World Health Organization World Health Organization. Available at: https://www.who.int/tools/whoqol#:~:text=WHOQOL%20%2D%20Measuring%20Quality%20of%20Life%7C%20The%20World%20Health%20Organization&text=WHO%20defines%20Quality%20of%20Life,%2C%20expectations%2C%20standards%20and%20concerns. (Accessed: 07 November 2017).

7. Vahedi S. World Health Organization Quality-of-Life Scale (WHOQOL-BREF): Analyses of Their Item Response Theory Properties Based on the Graded Responses Model. Iranian Journal of Psychiatry. 2010; 5(4): 140–153.

8. Aron, L. and Woolf, S.H. (2013) U.S. Health in International Perspective Shorter Lives, Poorer Health. Washington, D.C: National Academies Press.

9. Rooney, K. L., and Domar, A. D. The relationship between stress and infertility. Dialogues in clinical neuroscience, 2018; 20(1): 41–47. https://doi.org/10.31887/DCNS.2018.20.1/klrooney

10. Hasanpoor-Azghdy, S. B., Simbar, M., and Vedadhir, A. The emotional-psychological consequences of infertility among infertile women seeking treatment: Results of a qualitative study. Iranian Journal of Reproductive Medicine. 2014; 12(2): 131–138.

11. Montoya, J.M. Diagnostics in assisted human reproduction. Reproductive BioMedicine Online. 2002; 6(3): 198–210. doi:10.1016/s1472-6483(10)61843-3.

12. Group, T.E.C.W. (2000) Optimal use of infertility diagnostic tests and treatments, OUP Academic. Available at: https://doi.org/10.1093/humrep/15.3.723 (Accessed: 03 March 2017).

13. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012–. Gonadotropins. 2018 Mar 26. PMID: 31644163.

14. Khazeni, S. and Varamini, P. (2018) ‘Gonadotropin releasing hormone’, Reference Module in Biomedical Sciences [Preprint]. doi:10.1016/b978-0-12-801238-3.98031-0.

15. Das, N. and Kumar, T.R. Molecular regulation of follicle-stimulating hormone synthesis, secretion and action. Journal of Molecular Endocrinology. 2018; 60(3). doi:10.1530/jme-17-0308.

16. Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., Christman, G. M., Huang, H., Yan, Q., Alvero, R., Haisenleder, D. J., Barnhart, K. T., Bates, G. W., Usadi, R., Lucidi, S., Baker, V., Trussell, J. C., Krawetz, S. A., Snyder, P., Ohl, D., NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. The New England Journal of Medicine. 2014; 371(2): 119–129. https://doi.org/10.1056/NEJMoa1313517

Received on 26.09.2023 Modified on 23.12.2023

Res. J. Pharmacology and Pharmacodynamics. 2024;16(2):80-84.

DOI: 10.52711/2321-5836.2024.00014